Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
39.07
+1.37 (3.63%)
Sep 11, 2025, 4:00 PM EDT - Market closed
Exelixis Revenue
Exelixis had revenue of $568.26M in the quarter ending June 30, 2025, a decrease of -10.82%. This brings the company's revenue in the last twelve months to $2.23B, up 10.73% year-over-year. In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth.
Revenue (ttm)
$2.23B
Revenue Growth
+10.73%
P/S Ratio
4.91
Revenue / Employee
$1,944,207
Employees
1,147
Market Cap
10.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EXEL News
- 1 day ago - Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha
- 2 days ago - Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 8 days ago - Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 8 days ago - Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript) - Seeking Alpha
- 13 days ago - Exelixis Announces Appointment of Dana T. Aftab, Ph.D. - Business Wire
- 15 days ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September - Business Wire
- 17 days ago - Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters - Seeking Alpha